Background and objective: Bronchial thermoplasty (BT) has been shown to be effective at reducing asthma exacerbations and improving asthma control for patients with severe persistent asthma but it is also expensive. Evidence on its cost-effectiveness is limited and inconclusive. In this study, we aim to evaluate the incremental cost-effectiveness of BT combined with optimized asthma therapy (BT-OAT) relative to OAT for difficult-to-treat and severe asthma patients in Singapore, and to provide a general framework for determining BT's cost-effectiveness in other healthcare settings. Methods: We developed a Markov model to estimate the costs and quality-adjusted life years (QALYs) gained with BT-OAT versus OAT from the societal and health system perspectives. The model was populated using Singapore-specific costs and transition probabilities and utilities from the literature. Sensitivity analyses were conducted to identify the main factors determining cost-effectiveness of BT-OAT. Results: BT-OAT is not cost-effective relative to OAT over a 5-year time horizon with an incremental costeffectiveness ratio (ICER) of $US138 889 per QALY from the societal perspective and $US139 041 per QALY from the health system perspective. The cost-effectiveness of BT-OAT largely depends on a combination of the cost of the BT procedure and the cost of asthma-related hospitalizations and emergency department (ED) visits. Conclusion: Based on established thresholds for costeffectiveness, BT-OAT is not cost-effective compared with OAT in Singapore. Given its current clinical efficacy, BT-OAT is most likely to be cost-effective in a setting where the cost of BT procedure is low and costs of hospitalization and ED visits are high.
INTRODUCTION
Severe asthma affects 5-20% of all asthma patients but accounts for 50-80% of total asthma healthcare utilization and resources. 1 Patients with severe asthma often do not respond to maximal treatment with inhaled therapy and even long-term oral corticosteroids and still suffer from high morbidity and recurrent exacerbations. 2 Bronchial thermoplasty (BT) is a novel treatment for severe asthma. It delivers controlled thermal energy to the airway wall during a series of three bronchoscopy procedures (each procedure lasts 3 weeks for a total duration of 14 weeks), resulting in a prolonged reduction in airway smooth muscle mass and contractility. This, in turn, reduces bronchoconstriction and airflow obstruction and consequently, lowers exacerbation risks and improves asthma control. 3, 4 BT has been approved by the US Food and Drug Administration and is attracting increasing interest from the medical community as a treatment for severe asthma patients who are symptomatic despite high-dose inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs). Compared with a sham procedure, BT was found to lead to a 32% reduction in severe asthma exacerbations and a 66% reduction in number of days lost from work, school or other daily activities because of asthma symptoms. 5 Despite its clinical effectiveness, BT is expensive. A full course of BT treatment costs approximately $US17 000 in Singapore. This raises the question of whether BT is an efficient use of scarce healthcare resources. There is limited evidence on the costeffectiveness of BT. Only three studies have looked at the incremental cost-effectiveness of BT treatment relative to optimized asthma therapy (OAT) (the current Is bronchial thermoplasty cost-effective Exacerbation to death 0.000425 18 
OAT
Well to hospitalization 0.017 16, 17 Well to ED visit 0.036 16, 17 Well to physician visit 0.057 6, 16 Exacerbation Costs in Singapore dollars were converted to US dollars using exchange rate: S$1 = $US0.74. † First value corresponds to the probability during the BT treatment and second value to probability in post-treatment period. ‡ The first value corresponds to the cost for the group that continues on the usual medication dosage. The second value is the cost for the group for whom BT reduces medication need.
§ Nine days off work for BT treatment × $US111 per day; 4.6 days off work for hospitalization × $US111 per day; 2 days off work for exacerbation requiring ED/physician visit × $US111 per day.
¶ The value 0.0223 corresponds to the utility during the BT treatment. The value 0.0269 corresponds to the utility in post-treatment period. BT, bronchial thermoplasty; BT-OAT; BT combined with OAT; ED, emergency department; OAT, optimized asthma therapy.
standard of care) but their findings are mixed. [6] [7] [8] Further, while informative, the generalizability of these studies is questionable as they all utilize cost data from the US characterized by a unique combination of relatively low costs of the BT procedure 6 and relatively high costs of hospitalization. 9 As BT reduces the risk of exacerbation-related hospitalizations, cost of hospitalization (and BT procedure) greatly influences the costeffectiveness of BT.
Our paper has two objectives. First, we estimate the cost-effectiveness of BT relative to OAT in Singapore, a developed city-state that is contemplating whether to subsidize BT as a treatment for difficult-to-treat and severe asthma patients. Second, to provide a framework for other countries to determine the costeffectiveness of BT specific to their healthcare settings, we identify the conditions for BT to be cost-effective relative to OAT.
METHODS

Model structure and study cohort
We developed a Markov model to calculate the costs and quality-adjusted life years (QALYs) gained for a hypothetical cohort of patients with 'problematic asthma' who receive either both BT and OAT (BT-OAT, hereafter) or OAT alone. OAT comprises maximal inhaled asthma therapy including high-dose ICS and LABA combination inhalers and rescue therapy if required and specialist asthma care.
Problematic asthma encompasses both difficult and severe asthma. 10 Difficult asthma refers to asthma that is uncontrolled despite high-intensity treatment because of poor compliance, psychosocial factors, environmental exposures or co-morbidities. Severe asthma refers to patients with truly refractory disease requiring high-intensity treatment after excluding factors that may aggravate or complicate asthma. 11, 12 In addition, all patients fulfilled American Thoracic Society/European Respiratory Society (ATS/ERS) criteria for uncontrolled disease. 13 Our model simulated a patient's transition between five health states (i.e. well-controlled asthma, exacerbation requiring hospitalization, exacerbation requiring an emergency department (ED) visit, exacerbation requiring a physician visit and asthma-related death). Allowable transitions among these health states are displayed in Figure 1 .
A patient in the well-controlled state either remained in that state or experienced an exacerbation requiring hospitalization, an ED visit or a physician visit. If a patient required hospitalization, she/he either recovered and returned to the well-controlled asthma state or died. For patients treated in an ED or who visited a physician, we assumed they all returned to the wellcontrolled state.
We populated the model with local data on costs and data on QALYs from the published literature. The cycle length was set at 2 weeks given that asthma exacerbations are dynamic and depend on several factors including seasons and weather. The time horizon was set at 5 years as this is the duration for which BT's clinical effectiveness data are available.
14 All QALYs and costs were discounted at 3.5% per year following the UK's National Institute for Health and Care Excellence (NICE) guideline. 15 This study was exempted from review by the Singhealth Centralised Institutional Review Board (2014/046/C).
Model inputs Transition probabilities
All model inputs are displayed in Table 1 . Transition probabilities from the well-controlled state to exacerbation state differ between OAT and BT-OAT and depend on whether the exacerbation requires hospitalization, ED or physician visits. For the OAT strategy, transition probabilities from a well-controlled state to exacerbation state were based on exacerbation rates observed in a Singaporean cohort of problematic asthma patients who received maximal medical therapy. 16 To obtain the transition probabilities for the BT-OAT strategy, transition probabilities in the OAT strategy are multiplied by the relative risk of exacerbation after BT therapy estimated in the Asthma Intervention Research 2 (AIR2) trial. 6, 17 We used a higher relative risk ratio for the initial 14 weeks to account for the higher risk of exacerbation witnessed in the AIR2 trial during the BT treatment period. The annual probability of death following hospitalization was obtained from Sullivan et al. 18 All annual probabilities were converted to biweekly probabilities to accommodate the use of 2-week cycle.
Costs
We adopted both the health system and societal perspectives in estimating costs. 25 Under the societal perspective, costs consisted of both medical and nonmedical costs (i.e. work time lost). Under the health system perspective, only medical costs were included.
Medical costs of OAT included costs of ICS, LABA and rescue therapy, if prescribed. Medical costs of BT-OAT included cost of the BT procedure (procedural costs, device and consumables), the cost of medications and the cost of hospital stay after each BT session. Medical costs in both strategies also included the cost of medications and cost of managing exacerbations. All costs were obtained from local sources in 2015 Singapore dollars and converted to US dollars (using exchange rate as on 5 June 2016: S$1 = $US0.74). Further details on cost estimation are given in Appendix S1 (Supplementary Information).
Effectiveness
Effectiveness was measured in terms of QALYs gained. Utility weights were specific to health states and reflected the morbidity associated with asthma exacerbations. These were obtained from the literature. 6, 24 In particular, utility of being in the 'well-controlled' state with OAT was obtained from Campbell et al. 24 while the same for BT-OAT was taken from Cangelosi et al. 6 Utility during exacerbations was sourced from Campbell et al. 24 (further details are provided in Appendix S2, Supplementary Information). Because of initial disutility associated with the BT treatment, a lower utility value was assigned for the first 14 weeks for patients in the well-controlled state undergoing the BT treatment. Beyond 14 weeks, patients in the well-controlled state in the BT-OAT strategy experienced higher quality of life compared with their counterparts who did not undergo BT treatment. Annual utility weights were converted to biweekly utility to be consistent with the 2-week cycle length.
Cost-effectiveness analysis
We used Markov model to estimate the costs and effectiveness of BT-OAT and OAT strategies, both from the healthcare system and societal perspectives. Incremental cost-effectiveness ratio (ICER) is the difference between overall costs of the two strategies divided by the difference in QALYs. To account for uncertainty, one-way, two-way and probabilistic sensitivity analyses were conducted. All sensitivity analyses were conducted from healthcare system perspective. All costs were varied over a reasonably large range (AE50% of mean). We also conducted threshold analysis to identify the threshold values of key inputs that determine the cost-effectiveness of BT-OAT. Table 2 displays the cost-effectiveness results from the health system perspective. Compared with OAT, BT-OAT costs more ($US26 323 vs $US11 175) while generating greater QALYs (3.13 vs 3.02). Accordingly, the ICER of BT-OAT relative to OAT is $US139 041 per QALY gained. Using the societal perspective, panel (B) of Table 2 shows that BT-OAT again costs more than OAT ($US28 341 vs $US13 210) but also yields more QALYs (3.13 vs 3.02). The ICER of BT-OAT relative to OAT is $US138 889 per QALY gained. Compared with the conventional willingness to pay threshold of $US50 000 per QALY, BT-OAT is not costeffective compared with OAT from both the health system and societal perspectives.
RESULTS
Panel (A) of
Results from the one-way sensitivity analysis are presented in the Tornado diagram in Figure S1 (Supplementary Information). The ICER is most sensitive to the cost of the BT procedure and the cost of exacerbation-related hospitalizations. A more expensive BT procedure would increase the ICER, rendering BT less cost-effective. As BT reduces the risk of exacerbation-related hospitalizations, it would become more cost-effective when hospitalization costs are higher. The threshold analysis shows that all things being equal, reducing the cost of the BT procedure to $US7629 (i.e. $US2543 per session) would make BT-OAT cost-effective in Singapore (Fig. S2 , Supplementary Information). Figures 2 and 3 show different combinations of BT procedural cost and hospitalization/ED costs together with the corresponding cost-effectiveness of BT-OAT. For a specific level of hospitalization cost, one can infer a threshold value for BT procedural cost for which BT-OAT is cost-effective. For example, if the cost of hospitalization is $US5000 per episode (i.e. lower than the US but higher than Singapore), BT-OAT would be costeffective if the BT procedure was priced below $US8078. More generally, BT-OAT is likely to be costeffective when BT procedural costs are low and exacerbation-related hospitalization/ED costs are high. Conversely, BT-OAT is unlikely to be cost-effective in the case of high BT procedural costs and low costs of exacerbation-related hospitalization/ED. BT-OAT may or may not be cost-effective when costs of BT procedure and of exacerbation-related hospitalization/ED are high. Figure 4 displays the cost-effectiveness acceptability curves for BT-OAT and OAT. At the costeffectiveness threshold of $US50 000 per QALY, BT-OAT is cost-effective in only 42% of iterations.
We also considered cost-effectiveness of BT when it is offered to a subset of very severe asthma cases with frequent severe exacerbations (defined by ATS/ERS guideline as having had two or more ED visits or admissions in the past 1 year). 26 This is a group with substantial healthcare utilization and unmet needs. When we restricted the study population to this group (and conservatively assuming the same clinical effectiveness from AIR2 study), BT-OAT was still not costeffective although its ICER improved (i.e. declined from $US139 041/QALY to $US89 870/QALY).
DISCUSSION
This study found that BT-OAT is not cost-effective relative to OAT in Singapore. Our results stand in contrast with those of Cangelosi et al. 6 and Zein et al. 7 who found BT-OAT to be very cost-effective relative to OAT (ICER of $US5495/QALY and $US29 821/QALY, respectively). One-way and two-way sensitivity analyses suggest that the difference between the US and Singapore All costs are in US dollars ($US). BT, bronchial thermoplasty; BT-OAT; BT combined with OAT; ICER, incremental cost-effectiveness ratio; OAT, optimized asthma therapy; QALY, quality-adjusted life year.
in terms of the costs of BT and hospitalizations/ED explains this discrepancy. BT procedure is more expensive in Singapore ($US17 329) than in the US ($US14 100 in Cangelosi et al. 6 and $US6690 in Zein et al.). Moreover, the cost of an episode of exacerbation-related hospitalization is roughly three times greater in the US compared with Singapore ($US9801 vs $US3340) while cost of an ED visit is nearly eight times higher ($US673 vs $US85). Both the lower cost of the BT procedure and the higher cost of exacerbation-related hospitalizations lower the ICER for BT-OAT relative to OAT, making it very costeffective in the previously published analyses.
Apart from the differences in the costs of BT and hospitalization, our study differs from the US studies in a number of other aspects (Table S1 , Supplementary Information). First, our study population is slightly different as reflected in the different exacerbation rates compared with the US studies. Second, our study used the relative risk of exacerbation-related hospitalization after BT treatment from the AIR2 trial while the US studies used a different source. 27 Third, our model accounted for savings from lower medication costs attributed to BT 14 while the US studies did not. These differences, however, did not drive the divergent conclusions between our study and the US studies. When we re-ran our model using the same exacerbation rates and relative risks from Cangelosi et al. 6 and removed the medication cost advantage of BT, while keeping the Singapore-specific costs, BT-OAT was still not cost-effective: the ICER declined to $US105 598/ QALY but was still above the threshold of $US50 000/QALY.
It is worth noting that although Zafari et al. 8 also found that BT-OAT was not cost-effective relative to OAT with an ICER of $US78 700/QALY, their finding could be linked to the fact that they applied BT to both moderate and severe asthma patients. Meanwhile, our study focused on difficult and severe asthma cases. Inclusion of moderate asthma patients, who have a lower rate of exacerbations requiring hospitalization, in the cost-effectiveness analysis would dilute the BT's effectiveness and lower its cost-effectiveness.
Our study did not consider Omalizumab, a new alternative treatment, specifically for Step 5 asthma patients. However, previous studies that compared the cost-effectiveness of Omalizumab to BT found Omalizumab to be highly cost-ineffective with ICER as high as $US3.86 million/QALY. 8 Moreover, Omalizumab is only indicated for a subset of severe allergic asthma with IgE and body weight which are within the dosing range and thus not widely applicable to all severe asthma patients. 28 Our paper has a number of limitations. First, we only looked at a 5-year horizon because the clinical effectiveness for BT beyond 5 years is unknown. If BT's benefits extend beyond 5 years, BT-OAT's costeffectiveness could improve. Second, the threshold for referring asthma patients to hospital or EDs may vary across different healthcare systems, making our results less generalizable. However, to the extent that this decision may vary across physicians even within a healthcare system, the decision of an average physician in Singapore should be similar to that of a physician in other healthcare systems. Third, our study population was similar but not identical to the AIR2 population. There were two primary differences: (i) our population included patients with problematic asthma (severe or difficult asthma), whereas AIR2 consists only of severe asthma patients (details on the criteria for these classifications are provided in Appendix S3, Supplementary Information) and (ii) our study population was relatively older with median age of 56.1 years compared with 40.7 years in the AIR2 population. We chose to include patients with both severe and difficult asthma because these patients fulfil the ATS/ERS defined criteria for uncontrolled diseases and represent the greatest unmet need in asthma where BT is positioned as a therapeutic alternative. 12, 13 As there is no evidence that age moderates the effectiveness of BT, our older sample generates a more conservative ICER as older patients have less time to accrue the benefits of the procedure. Further, we note that AIR2 trial was not designed to primarily analyse rates of exacerbation. While our calculation of relative risk was based on the proportion of patients with exacerbations and thus was independent of any outliers in terms of patients' number of hospitalizations, it may still be affected if the sham and BT groups were not balanced at baseline for rates/risk of exacerbation. Finally, patients in the AIR2 trial were not phenotyped (no exhaled nitric oxide or sputum, serum eosinophil counts checked). Hence, the effectiveness of BT in specific patient subgroups such as those with eosinophilic asthma is unknown and our BT cost-effectiveness estimates might not apply to these patients. Willingness-to-pay 60 000 70 000 80 000 90 000 100 000 Figure 4 Cost-effectiveness acceptability curve. , BT-OAT, bronchial thermoplasty combined with optimized asthma therapy;
, no BT.
In conclusion, although BT-OAT generates more QALYs over 5 years than OAT, it is not a cost-effective strategy for treating problematic asthma patients in Singapore. Given the current clinical effectiveness of BT reported in the AIR2 study, cost-effectiveness of BT-OAT depends heavily on whether the cost of BT procedure is 'right' for the unique costs of asthma exacerbations that each healthcare system faces. Our study provides a novel framework for policymakers and clinicians to determine whether BT-OAT will be costeffective in their local contexts.
